The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials
Rehovot, Israel – January 13, 2020 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127
Rehovot, Israel – November 12, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today positive preliminary results from recently completed animal studies in its immuno-oncology program,
The company has in-licensed IP and knowhow generated by Prof. Ada E. Yonath, Nobel Prize winner, who will advise Biomica on the program
Rehovot, Israel – October 23, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
Aims to augment current cancer therapies by altering patients’ gut microbiome to improve response
Rehovot, Israel – April 16, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
This is the second program to enter pre-clinical studies; In addition, Prof. David T. Rubin, joins Biomica as a scientific & medical advisor
Rehovot, Israel – October 2nd, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics,
This addition to Biomica’s scientific expertise will support the company’s upcoming steps towards its clinical development
Rehovot, Israel – 06 November, 2018 – Biomica, a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics announced today that internationally renowned experts have joined the company’s scientific advisory board.
Rehovot, Israel – May 14, 2018 – Biomica, a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene’s Computational Predictive Biology (CPB) platform, announced today its participation at the Microbiome Invest Conference in London, May 23, 2018.
Biomica leverages proprietary Computational Predictive Biology platform tailored to develop human microbiome therapies for antibiotic resistant bacteria, Immuno-Oncology and GI related disorders
Rehovot, Israel – 01 May, 2018 –Biomica, a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene’s Computational Predictive Biology (CPB) platform,